Medicine · 2025
First case report of lorlatinib in the treatment of ALK-fusion-positive lung adenocarcinoma with ovarian metastasis: Clinicopathological and molecular characterization.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xu Tianxiang, Hua Shiyu, Wang Jingying, Wu Mengqi, Qiu Xinyi, Hong Jiamin, Zhang Yu, Shao Keding, Wang Jue
Аннотация
BACKGROUND: Ovarian metastasis from anaplastic lymphoma kinase (ALK)-positive lung adenocarcinoma is exceedingly rare. Reporting such cases is vital for understanding its clinical management.
PATIENT CONCERNS: A 49-year-old woman presented with a 10-day history of amenorrhea and lower abdominal pain.
DIAGNOSES: Imaging revealed bilateral ovarian masses and liver nodules. Liver biopsy and genetic testing confirmed the diagnosis of stage IV EML4-ALK fusion-positive lung adenocarcinoma with ovarian and hepatic metastases.
INTERVENTIONS: First-line treatment with the third-generation ALK inhibitor lorlatinib (100 mg, once daily) was initiated.
OUTCOMES: The patient achieved a partial response with significant lesion regression and normalized tumor markers, sustained for over 12 months. No severe adverse events occurred.
LESSONS: This case underscores the importance of molecular profiling in diagnosing metastatic tumors and confirms lorlatinib as a highly effective first-line therapy for ALK-positive non-small cell lung cancer with atypical metastases.
PATIENT CONCERNS: A 49-year-old woman presented with a 10-day history of amenorrhea and lower abdominal pain.
DIAGNOSES: Imaging revealed bilateral ovarian masses and liver nodules. Liver biopsy and genetic testing confirmed the diagnosis of stage IV EML4-ALK fusion-positive lung adenocarcinoma with ovarian and hepatic metastases.
INTERVENTIONS: First-line treatment with the third-generation ALK inhibitor lorlatinib (100 mg, once daily) was initiated.
OUTCOMES: The patient achieved a partial response with significant lesion regression and normalized tumor markers, sustained for over 12 months. No severe adverse events occurred.
LESSONS: This case underscores the importance of molecular profiling in diagnosing metastatic tumors and confirms lorlatinib as a highly effective first-line therapy for ALK-positive non-small cell lung cancer with atypical metastases.